News | April 15, 2009

Zecotek Photonics Earns Frost & Sullivan Enabling Technology Award

April 15, 2009 - Based on its recent analysis of the U.S. PET and PET/CT markets, Frost & Sullivan awarded Zecotek Photonics Inc. with its 2009 North American Frost & Sullivan Award for Enabling Technology.

According to Frost & Sullivan, Zecotek's outstanding research and development has brought forth innovative scintillation crystal and solid-state photo detector technologies that will help deliver cutting-edge oncology, neurology and cardiology imaging equipment.

"Zecotek is favorably positioned as a global competitor, having been issued or allowed patents for its lutetium fine silicate (LFS) scintillation crystals in many countries and a series of pending and granted patents for its novel solid-state photomultiplier and Depth of Interaction design considerations," said Travis Chong, an industry analyst for Frost & Sullivan. "The company is integrating all these components into what it has dubbed the 'Plug to Socket', a very compact detector module element that captures high resolution images, is easy to install, and requires very low servicing."

Zecotek has emerged as a leader in developing affordable, sophisticated photodetector and solid-state technologies for PET/CT and other medical applications. The company first set the standard with its micro-pixel avalanche photo diode (MAPD)-1 concept, whose design and performance characteristics served as a solid-state photodetector design template for the industry over the last several years. The MAPD-1 eventually evolved into the MAPD-2 and MAPD-3, providing better electrical efficiency and imaging capabilities than traditional integrated photo multiplier tubes (PMTs) in scanners.

For more information: www.frost.com, www.zecotek.com

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...